Cat.No：GM-87163MAB
Product：Anti-DLL3 hIgG1 Reference Antibody (Rovabio)
Cat.No：GM-87163MAB
Product：Anti-DLL3 hIgG1 Reference Antibody (Rovabio)
GM-87163MAB-1mg / 1 mg
GM-87163MAB-5mg / 5 mg
GM-87163MAB-25mg / 25 mg
GM-87163MAB-50mg / 50mg
GM-87163MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target DLL3
Clone Rovalpituzumab
Alternative Names SCDO1
Source/Isotype Human IgG1(KDEL,delta 447K), Kappa
Application Flow cytometry
Description Delta-like 3 (Drosophila), also known as DLL3, is a protein which in humans is encoded by the DLL3 gene. This gene encodes a member of the delta protein ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Expression of DLL3 is highest in fetal brain. It plays a key role in somitogenesis within the Paraxial mesoderm. Mutations in this gene cause the autosomal recessive genetic disorder Jarcho-Levin syndrome. Expression of the gene occurs in Neuroendocrine tumors, which has been targeted as a potential pathway for treatment. An experimental drug, rovalpituzumab tesirine, targets DLL3 as a possible treatment for lung cancer.
Formulation Phosphate-buffered solution, pH 7.4.
Cat.No：GM-87163MAB
Product：Anti-DLL3 hIgG1 Reference Antibody (Rovabio)
GM-87163MAB-1mg / 1 mg
GM-87163MAB-5mg / 5 mg
GM-87163MAB-25mg / 25 mg
GM-87163MAB-50mg / 50mg
GM-87163MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target DLL3
Clone Rovalpituzumab
Alternative Names SCDO1
Source/Isotype Human IgG1(KDEL,delta 447K), Kappa
Application Flow cytometry
Description Delta-like 3 (Drosophila), also known as DLL3, is a protein which in humans is encoded by the DLL3 gene. This gene encodes a member of the delta protein ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Expression of DLL3 is highest in fetal brain. It plays a key role in somitogenesis within the Paraxial mesoderm. Mutations in this gene cause the autosomal recessive genetic disorder Jarcho-Levin syndrome. Expression of the gene occurs in Neuroendocrine tumors, which has been targeted as a potential pathway for treatment. An experimental drug, rovalpituzumab tesirine, targets DLL3 as a possible treatment for lung cancer.
Formulation Phosphate-buffered solution, pH 7.4.
